Net loss for Q4/10 was $5.1 M. or $0.18 per share.
ASTM reported no revenues for Q4/10. R&D expenses for Q4/10 were $3.6 M with FY09 numbers (ended 6/30/10) coming in at $12.7 M. These changes reflect ASTM’s increased clinical activity related to its DCM and CLI programs. SG&A expenses for Q4/10 were $1.5 M and the FY09 were $5.2 million. These changes are primarily due to increased employment costs, external legal and consulting fees. Net loss for FY10 was $17.7 M, or $0.72 per share, compared to a net loss of $15.9 M, or $0.89 per share for FY09. The increase in net loss for FY 09 is primarily due to increased R&D costs. Loss per share comparisons were impacted by the issuance of 6.5 M shares of common stock on 1/21/10.
As of 6/30/10, the company had a total of $19.1M in cash, cash equivalents and short term investments. Aastrom expects that its cash spending will average approximately $4 – $5 M per quarter over the next 12 months which includes Phase 3 clinical program planning and initiation costs for the critical limb ischemia program.
ASTM has made significant progress during the past 12 months and are now in a much stronger position to execute our clinical programs and commercialize our autologous cell therapies,” said Tim Mayleben, president and CEO of Aastrom Biosciences:
- ASTM reported positive Phase 2b interim results in the treatment of critical limb ischemia,
- Expanded clinical research program in dilated cardiomyopathy,
- Raised more than $17 M in new capital,
- Executed a reverse stock split to improve our capital structure,
- Increased institutional ownership of our stock,
- Strengthened management team with several key appointments.
“Based on these achievements, we are now preparing to move our critical limb ischemia program into Phase 3 development, report final results from the ongoing Phase 2 CLI study, report interim data from the IMPACT-DCM study and complete the ongoing Phase 2 Catheter DCM trial.”